156 related articles for article (PubMed ID: 8439979)
1. Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
Weiner LM; Hudes GR; Kitson J; Walczak J; Watts P; Litwin S; O'Dwyer PJ
Cancer Immunol Immunother; 1993; 36(3):185-90. PubMed ID: 8439979
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
[TBL] [Abstract][Full Text] [Related]
3. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL
Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910
[TBL] [Abstract][Full Text] [Related]
4. Biochemical modulation of 5-fluorouracil by PALA.
O'Dwyer PJ
Cancer Invest; 1990; 8(2):261-2. PubMed ID: 2400945
[No Abstract] [Full Text] [Related]
5. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Kemeny N; Conti JA; Seiter K; Niedzwiecki D; Botet J; Martin D; Costa P; Wiseberg J; McCulloch W
J Clin Oncol; 1992 May; 10(5):747-52. PubMed ID: 1569447
[TBL] [Abstract][Full Text] [Related]
6. The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study.
Tsavaris NB; Katsoulas HL; Kosmas C; Papalambros E; Gouveris P; Papantoniou N; Rokana S; Kosmas N; Skopeliti M; Tsitsilonis OE
Oncology; 2004; 67(5-6):403-10. PubMed ID: 15713997
[TBL] [Abstract][Full Text] [Related]
7. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
Nassim MA; Rouini MR; Cripps MC; Shirazi FH; Veerasinghan S; Molepo JM; Obrocea M; Redmond D; Bates S; Fry D; Stewart DJ; Goel R
Oncol Rep; 1998; 5(1):217-21. PubMed ID: 9458325
[TBL] [Abstract][Full Text] [Related]
8. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Harte RJ; Matthews JC; O'Reilly SM; Tilsley DW; Osman S; Brown G; Luthra SJ; Brady F; Jones T; Price PM
J Clin Oncol; 1999 May; 17(5):1580-8. PubMed ID: 10334547
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
O'Dwyer PJ; Paul AR; Walczak J; Weiner LM; Litwin S; Comis RL
J Clin Oncol; 1990 Sep; 8(9):1497-503. PubMed ID: 2391557
[TBL] [Abstract][Full Text] [Related]
10. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.
Wils J; Blijham GH; Wagener T; De Greve J; Jansen RL; Kok TC; Nortier JW; Bleiberg H; Couvreur ML; Genicot B; Baron B;
Eur J Cancer; 2003 Feb; 39(3):346-52. PubMed ID: 12565987
[TBL] [Abstract][Full Text] [Related]
11. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H
J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Kemeny N; Schneider A; Martin DS; Colofiore J; Sawyer RC; Derby S; Salvia B
Cancer Res; 1989 Aug; 49(16):4636-9. PubMed ID: 2472883
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma.
Wadler S; Gleissner B; Hilgenfeld RU; Thiel E; Haynes H; Kaleya R; Rozenblit A; Kreuser ED
Eur J Cancer; 1996 Jun; 32A(7):1254-6. PubMed ID: 8758262
[TBL] [Abstract][Full Text] [Related]
14. The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer.
Nichols PH; Ward U; Ramsden CW; Primrose JN
Br J Cancer; 1994 Nov; 70(5):946-9. PubMed ID: 7947102
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
Martino RL; Fleming TR; Morrell LM; Ardalan B; Richman SP; Macdonald JS
Invest New Drugs; 1996; 14(4):419-21. PubMed ID: 9157080
[TBL] [Abstract][Full Text] [Related]
17. A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study.
Morrell LM; Bach A; Richman SP; Goodman P; Fleming TR; MacDonald JS
Cancer; 1991 Jan; 67(2):363-6. PubMed ID: 1985731
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
Fleming RA; Capizzi RL; Muss HB; Smith S; Fernandes DJ; Homesley H; Loggie BW; Case L; Morris R; Russell GB; Richards F
Clin Cancer Res; 1996 Jul; 2(7):1107-14. PubMed ID: 9816275
[TBL] [Abstract][Full Text] [Related]
20. Sparfosate. A novel biomodulator of 5-fluorouracil.
Koshland P; Maa L; Ignoffo R
Cancer Pract; 1999; 7(4):212-6. PubMed ID: 10687588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
